Dr. Bailey Discusses the Treatment of Pediatric Patients With Sarcoma

Video

In Partnership With:

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Bailey says that while physicians have their go-to cytotoxic therapy for the treatment of osteosarcoma or Ewing sarcoma at relapse, there are many exciting agents in development. For example, there is an LSD-1 inhibitor in development, as well as inhibitors trying to target the EWS/FLI-1 fusion protein in Ewing sarcoma. There are a lot of exciting agents out there, Bailey says, but without biopsy information, the optimal use of these agents is unknown.

A tissue biopsy is recommended when a patient relapses, Bailey says. Although, the concept of liquid biopsies and circulating tumor DNA (ctDNA) may be a way to detect relapse or persistent disease at a low level when there is no radiographic evidence. Also, observing the circulating tumors cells and ctDNA are a way to monitor how tumors change over time, Bailey adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,